Pipeline

Scientific Publications & Presentations

ASCO Annual Meeting (June 5, 2016)

Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Glioblastoma

American Association of Cancer Research (AACR) Annual Meeting (April 19, 2016)

Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioblastoma

American Association of Cancer Research (AACR) Annual Meeting (April 19, 2016)

Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Cancer Treatment

American Association of Cancer Research (AACR) Annual Meeting (April 18, 2016)

Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: impact of p53 and platinum-resistance

Society for Neuro-Oncology Poster (November 20, 2015)

Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma

AACR New Horizons in Cancer Research Conference: Bringing Cancer Discoveries to Patients (November 13, 2015)

The unique mechanism of action of dianhydrogalactitol (VAL-083) may provide a new treatment option for chemo-resistant cancers

AACR Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship (November 10, 2015)

Dianhydrogalactitol (VAL-083) Offers Potential Therapeutic Alternatives in the Treatment of Pediatric Brain

2015 Canadian Cancer Research Conference (November 9, 2015)

Exploring the Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Cancer Treatment

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (November 6, 2015)

Dianhydrogalactitol (VAL-083) enhances activity of platinum drugs in non-small cell lung cancer

American Association for Cancer Research (AACR) Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Conference (October 19, 2015)

A comparison of mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to cisplatin in ovarian tumor models harbouring wild-type and mutant p53

GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain (September 9-12, 2015)

Tuesday, September 8, 2015 poster session Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma

16th World Conference on Lung Cancer, Denver, Colorado (September 6-9, 2015)

Tuesday, September 8, 2015 poster session Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer

ASCO Annual Meeting, Chicago, Illinois (May 29-June 2, 2015)

Monday, June 1, 2015 poster session Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma Multiforme (GBM)

106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania (April 18-22, 2015)

Monday, April 20, 2015 poster session VAL-083 GBM preclinical poster #2562: Dianhydrogalactitol inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo‚Äã‚Äã

Monday, April 20, 2015 poster session VAL-083 Phase 1/2 data poster # CT217: Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma

Sunday, April 19, 2015 poster session VAL-083 NSCLC preclinical poster # 751: In vitro activity of dianhydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer